Gynecologic Cancers ESMO 2023: Adding a PARP Inhibitor to Chemoimmunotherapy in Advanced Endometrial Cancer
Gynecologic Cancers ASCO 2022: Real-World Data on Maintenance Olaparib in BRCA-Mutated Ovarian Cancer
Gynecologic Cancers Rucaparib vs Standard-of-Care Chemotherapy for BRCA1/2-Mutated, Relapsed Ovarian Cancer
Head & Neck/Thyroid Cancer Perioperative Pembrolizumab Plus Standard of Care for Resectable Locally Advanced HNSCC
Genitourinary Cancers Radiopharmaceuticals for Treatment of Metastatic Castration-Resistant Prostate Cancer
